Table 2 Comparison of ATD-treated Graves’ disease patients who achieved remission versus patients who did not achieve remission
From: Efficacy of Anti-Thyroid Medications in Patients with Graves’ Disease
Variable | Remission (n = 103) | No remission (n = 86) | P-value |
|---|---|---|---|
Age (years), n, [Median (IQR)] | 103,[39.0( 34.00, 50.00)] | 86,[38.0( 31.00, 49.00)] | 0.484^ |
Free T3 upon diagnosis(pmol/l), n, [Median (IQR)] | 103,[9.2( 7.00, 15.80)] | 82,[11.1( 6.40, 23.60)] | 0.177^ |
Free T4 upon diagnosis(pmol/l), n, [Mean (SD)] | 103,[25.8 ( 8.93 )] | 86,[28.8 ( 10.82)] | 0.038* |
TSH receptor antibodies level up on diagnosis(IU/l), n, [Median (IQR)] | 93,[5.1( 2.90, 10.70)] | 73,[10.5( 4.20, 22.50)] | 0.001^ |
Thyroid uptake on 99mTc-pertechnetate scan (%),n, [Median (IQR)] | 79,[7.8( 3.77, 14.70)] | 61,[10.5( 4.77, 21.50)] | 0.061^ |
BMI (Kg/m2), n, Mean (SD) | 103,[28.8 ( 5.88 )] | 86,[ 29.4 ( 6.40 )] | 0.485* |
Duration of ATDs treatment (months), n, [Median (IQR)] | 103,[29.0( 20.00, 42.00)] | 86,[33.0( 23.00, 53.00)] | 0.154^ |
Female patients, n (%) | 84 ( 81.6 ) | 52 ( 60.5 ) | 0.001** |
Male patients, n (%) | 19 ( 18.4 ) | 34 ( 39.5 ) | 0.001** |
Mild ophthalmopathy, n (%) | 81 ( 84.4 ) | 48 ( 56.5 ) | < 0.0001** |
Moderate or severe ophthalmopathy, n (%) | 15 ( 15.6 ) | 37$ ( 43.5 ) | < 0.0001** |